Literature DB >> 20665127

Reprogramming of human umbilical cord stromal mesenchymal stem cells for myogenic differentiation and muscle repair.

Cetin Kocaefe1, Deniz Balci, Burcu Balci Hayta, Alp Can.   

Abstract

Human umbilical cord stromal mesenchymal stem cells (hUCS-MSCs) have the potential to differentiate into numerous cell types including epithelial cells, neurons and hepatocytes in vitro, in addition to mesenchyme-derived cells such as osteocytes, chondrocytes and adipocytes. One important property of these cells is the lack of type II major histocompatibility complex class molecules, thus allowing them to be considered as an excellent candidate for transplantations. Besides the use of 5-azacytidine as a supraphysiological inducer of myogenic transformation, no study has been published to date addressing the myogenic transformation efficiency of hUCS-MSCs by using a gene transfection strategy and/or co-culture with muscle cell lines. Here, we demonstrate the reprogramming efficiency of these cells, which differentiate into myocytes in vitro by MyoD transcription factor, the master regulator of skeletal muscle differentiation. Once induced via MyoD expression, hUCS-MSCs exhibited many cellular signs of myogenic conversion within 5 days and became capable of forming multinucleated myofibers, which exhibited all functional markers of fusion machinery such as β-catenin, neural cell adhesion molecule and M-cadherin as well as muscle cell-specific structural proteins including desmin, α-actinin, dystrophin, myosin heavy chain, and myoglobin together with muscle-specific enzyme, creatinine phosphokinase. Furthermore, programmed hUCS-MSCs were also capable of fusing with rat primary myoblasts to form heterokaryonic myotubes. Taken together, this study demonstrates the success of a novel cell reprogramming approach to be further evaluated at the in vivo level for use in restoring the defective dystrophin function as intrinsically found in the skeletal muscle fibers of Duchenne muscular dystrophy patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20665127     DOI: 10.1007/s12015-010-9177-7

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  30 in total

1.  Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord.

Authors:  Hwai-Shi Wang; Shih-Chieh Hung; Shu-Tine Peng; Chun-Chieh Huang; Hung-Mu Wei; Yi-Jhih Guo; Yu-Show Fu; Mei-Chun Lai; Chin-Chang Chen
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

2.  Acquisition and extinction of gene expression programs are separable events in heterokaryon reprogramming.

Authors:  Rémi Terranova; Carlos Filipe Pereira; Camille Du Roure; Matthias Merkenschlager; Amanda G Fisher
Journal:  J Cell Sci       Date:  2006-04-25       Impact factor: 5.285

3.  Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials.

Authors:  Lu-Lu Lu; Yong-Jun Liu; Shao-Guang Yang; Qin-Jun Zhao; Xin Wang; Wei Gong; Zhi-Bo Han; Zhen-Shu Xu; Yong-Xin Lu; Delong Liu; Zhi-Zhe Chen; Zhong-Chao Han
Journal:  Haematologica       Date:  2006-07-25       Impact factor: 9.941

4.  Reproducible methodology for the isolation of mesenchymal stem cells from human umbilical cord and its potential for cardiomyocyte generation.

Authors:  Winston Costa Pereira; Italia Khushnooma; Manisha Madkaikar; K Ghosh
Journal:  J Tissue Eng Regen Med       Date:  2008-10       Impact factor: 3.963

5.  Recombinational construction in Escherichia coli of infectious adenoviral genomes.

Authors:  J Crouzet; L Naudin; C Orsini; E Vigne; L Ferrero; A Le Roux; P Benoit; M Latta; C Torrent; D Branellec; P Denèfle; J F Mayaux; M Perricaudet; P Yeh
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

6.  Bone marrow stromal cells generate muscle cells and repair muscle degeneration.

Authors:  Mari Dezawa; Hiroto Ishikawa; Yutaka Itokazu; Tomoyuki Yoshihara; Mikio Hoshino; Shin-ichi Takeda; Chizuka Ide; Yo-ichi Nabeshima
Journal:  Science       Date:  2005-07-08       Impact factor: 47.728

7.  A myogenic cell line with altered serum requirements for differentiation.

Authors:  D Yaffe; O Saxel
Journal:  Differentiation       Date:  1977       Impact factor: 3.880

8.  Naïve human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo.

Authors:  Rie Ayuzawa; Chiyo Doi; Raja Shekar Rachakatla; Marla M Pyle; Dharmendra Kumar Maurya; Deryl Troyer; Masaaki Tamura
Journal:  Cancer Lett       Date:  2009-03-13       Impact factor: 8.679

9.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

Review 10.  Mesenchymal stem cells: biology and clinical potential in type 1 diabetes therapy.

Authors:  Meng Liu; Zhong Chao Han
Journal:  J Cell Mol Med       Date:  2008-02-24       Impact factor: 5.310

View more
  14 in total

Review 1.  Concise review: mesoangioblast and mesenchymal stem cell therapy for muscular dystrophy: progress, challenges, and future directions.

Authors:  Suzanne E Berry
Journal:  Stem Cells Transl Med       Date:  2014-11-12       Impact factor: 6.940

Review 2.  Musculoskeletal tissue engineering with human umbilical cord mesenchymal stromal cells.

Authors:  Limin Wang; Lindsey Ott; Kiran Seshareddy; Mark L Weiss; Michael S Detamore
Journal:  Regen Med       Date:  2011-01       Impact factor: 3.806

3.  Recent Patents Pertaining to Immune Modulation and Musculoskeletal Regeneration with Wharton's Jelly Cells.

Authors:  Limin Wang; Mark L Weiss; Michael S Detamore
Journal:  Recent Pat Regen Med       Date:  2013

4.  Human Umbilical Cord Mesenchymal Stromal Cell Transplantation in Myocardial Ischemia (HUC-HEART Trial). A Study Protocol of a Phase 1/2, Controlled and Randomized Trial in Combination with Coronary Artery Bypass Grafting.

Authors:  Alp Can; Ahmet Tulga Ulus; Ozgur Cinar; Ferda Topal Celikkan; Erdal Simsek; Mesut Akyol; Ugur Canpolat; Murat Erturk; Fadil Kara; Osman Ilhan
Journal:  Stem Cell Rev Rep       Date:  2015-10       Impact factor: 5.739

5.  Continual expression throughout the cell cycle and downregulation upon adipogenic differentiation makes nucleostemin a vital human MSC proliferation marker.

Authors:  Pinar Akpinar Oktar; Sibel Yildirim; Deniz Balci; Alp Can
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

6.  Fast-degradable microbeads encapsulating human umbilical cord stem cells in alginate for muscle tissue engineering.

Authors:  Jun Liu; Hongzhi Zhou; Michael D Weir; Hockin H K Xu; Qianming Chen; Carroll Ann Trotman
Journal:  Tissue Eng Part A       Date:  2012-07-19       Impact factor: 3.845

7.  The vasorelaxant effect of hydrogen sulfide is enhanced in streptozotocin-induced diabetic rats.

Authors:  Merve Denizalti; Turgut Emrah Bozkurt; Uğur Akpulat; Inci Sahin-Erdemli; Nurettin Abacıoğlu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-03-11       Impact factor: 3.000

8.  Human umbilical cord stem cell encapsulation in novel macroporous and injectable fibrin for muscle tissue engineering.

Authors:  Jun Liu; Hockin H K Xu; Hongzhi Zhou; Michael D Weir; Qianming Chen; Carroll Ann Trotman
Journal:  Acta Biomater       Date:  2012-08-16       Impact factor: 8.947

Review 9.  Epigenetics of insulin resistance: an emerging field in translational medicine.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  Curr Diab Rep       Date:  2013-04       Impact factor: 4.810

10.  Systemic delivery of human mesenchymal stromal cells combined with IGF-1 enhances muscle functional recovery in LAMA2 dy/2j dystrophic mice.

Authors:  Mariane Secco; Carlos Bueno; Natassia M Vieira; Camila Almeida; Mayra Pelatti; Eder Zucconi; Paolo Bartolini; Mariz Vainzof; Elen H Miyabara; Oswaldo K Okamoto; Mayana Zatz
Journal:  Stem Cell Rev Rep       Date:  2013-02       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.